Brief trains of action potentials enhance pyramidal neuron excitability via endocannabinoid-mediated suppression of inhibition.
Depolarization-induced suppression of inhibition (DSI) is a form of retrograde signaling at GABAergic synapses that is initiated by the calcium- and depolarization-dependent release of endocannabinoids from postsynaptic neurons. In the neocortex, pyramidal neurons (PNs) appear to use DSI as a mechanism for regulating somatic inhibition from a subpopulation of GABAergic inputs that express the type 1 cannabinoid receptor. Although postsynaptic control of afferent inhibition may directly influence the integrative properties of neocortical PNs, little is known about the patterns of activity that evoke endocannabinoid release and the impact such disinhibition may have on the excitability of PNs. Here we provide the first systematic survey of action potential (AP)-induced DSI in the neocortex. The magnitude and time course of DSI was directly related to the number and frequency of postsynaptic APs with significant suppression induced by a 20-Hz train containing as few as three APs. This AP-induced DSI was mediated by endocannabinoids as it was prevented by the cannabinoid receptor antagonist AM251 and potentiated by the endocannabinoid transport inhibitor AM404. We also explored the effects of endocannabinoid-mediated DSI on PN excitability. We found that single AP trains markedly increased PN responsiveness to excitatory synaptic inputs and promoted AP discharge by suppressing GABAergic inhibition. The time course of this effect paralleled DSI expression and was completely blocked by AM251. Taken together, our data suggest a role for endocannabinoids in regulating the output of cortical PNs.
Fortin
Dale A
DA
Dept. of Pharmacology, MC-6125, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT 06030, USA.
Trettel
Joseph
J
Levine
Eric S
ES
D000200:Action Potentials / Q000502:physiology*; D000818:Animals; D048588:Benzoxazines; D063385:Cannabinoid Receptor Modulators / Q000502:physiology*; D002217:Carbachol / Q000494:pharmacology; D004558:Electric Stimulation; D004594:Electrophysiology; D063388:Endocannabinoids; D019706:Excitatory Postsynaptic Potentials / Q000502:physiology; D007700:Kinetics; D051379:Mice; D018715:Microscopy, Video; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D019579:Neocortex / Q000502:physiology; D018722:Nicotinic Agonists / Q000494:pharmacology; D010275:Parasympathetic Nervous System / Q000502:physiology; D017966:Pyramidal Cells / Q000502:physiology*; D043882:Receptors, Cannabinoid / Q000187:drug effects; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D048588:Benzoxazines; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D009025:Morpholines; D009281:Naphthalenes; D018722:Nicotinic Agonists; D043882:Receptors, Cannabinoid; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D002217:Carbachol